Significance of rosiglitazone inhibiting TLR4 expression in partial hepatic ischemia/reperfusion of mice

Abstract

The effect of rosiglitazone as the ligand of peroxisome proliferator-activated receptor γ (PPARγ) inhibiting the TLR4 expression in ischemic lobes in partial hepatic ischemia/reperfusion injury (IRI) in BABL/C mice and the action of rosiglitazone inhibiting the TLR4 receptor-mediated inherent immune response were investigated. The model of the mouse partial hepatic ischemia/reperfusion injury was established. All the animals were randomly divided into 3 groups: rosiglitazone group, vehicle (dimethylsulphoxide, DMSO) group and sham operation group. The hepatic samples were collected when mice were sacrificed 0, 2, 4 and 6 h after reperfusion following 1 h ischemia to analyze the acute phase of hepatic IRI. The dynamic expression of TIR4 mRNA was detected quantitatively by real-time-PCR, and the levels of TNF-α, IL-10 and ALT in portal vein were determined in all groups. After restoration of blood supply, the expression of TLR4 mRNA in ischemic lobes was detected in 0, 2, 4 and 6 h after reperfusion following 1 h ischemia in rosiglitazone group and vehicle group. The most intensive expression of TLR4 mRNA was present at 4 h after reperfusion in ischemic lobes in vehicle group. As compared with vehicle group, the expression of TLR4 mRNA in ischemic lobes in rosiglitazone group was significantly decreased at 4 h after reperfusion. The level of IL-10 in portal vein was markedly up-regulated in rosiglitazone group as compared with vehicle group. Contrarily, the levels of TNF-α and ALT in portal vein were markedly down-regulated in rosiglitazone group as compared with vehicle group at every time point in mouse partial hepatic IRI model. Rosiglitazone could alleviate the hepatic IRI by inhibiting TLR4 receptor-mediated inherent immune response.

Keywords

hepatic reperfusion injury / toll-like receptor / rosiglitazone / peroxisome proliferator-activated receptor γ

References

[1] ConstantinoF., RonaldW. B., JerzyW. K., et al.. Hepatic ischemia/reperfusion injury—a fresh look. Exp Mol Pathol, 2003, 74: 86

[2] NakajimaA., WadaK., MikiH., et al.. Endogenous PPARγ mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology, 2001, 120: 460-469

[3] LawlorD. K., BrockR. W., HarrlsK. A., et al.. Cytokines contribute to early hepatic parenchymal injury and microvascular dysfuntion after bilateral hind limb ischemia. J Vasc Surg, 1999, 30(4): 533-541

[4] YoshidomeH., KatoA., EdwardsM. J., et al.. Interleukin-10 suppresses hepatic-ischemia reperfusion injury in mice: implications of a control role for nuclear factor kappaB. Hepatology, 1999, 30(2): 203-208

[5] Le MoineO., LouisH., DemolsA., et al.. Cold liver ischemia/reperfusion injury critically depends on liver T cells and is improved by donor pretreatment with interleukin 10 in mice. Hepatology, 2000, 31(6): 1266-1274

[6] MurphyG. J., HolderJ. C.. PPAR-g agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci, 2000, 21: 469-474

[7] PascualL. G., GlassC. K.. Peroxisome proliferator-activat ed receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol, 2000, 20: 4699-4707

[8] JiangC., TingA. T., SeedB.. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature, 1998, 391: 82-86

[9] WadaK., NakajimaA., TakahashiH., et al.. Protective effect of endogenous PPARγ against acute gastric mucosal lesions associated with ischemia-reperfusion. Am J Physiol Gastrointest Liver Physiol, 2004, 287: G452-G458

[10] CuzzocreaS., PisanoB., DugoL., et al.. Rosiglitazone and 5-deoxy-delta12, 14-preostaglandinJ2, ligand of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischemia/reperfusion injury of the gut. Br J Pharmacol, 2003, 140: 366-376

[11] TakedaK., KaishoT., AkiraS.. Toll-like receptors. Annu Rev Immunol, 2003, 21: 335-376

[12] ZhaiY., ShenX. D., O’ConnellR., et al.. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent Pathway. J Immunol, 2004, 173: 7115-7119

[13] AppelS., MirakajV., BringmannA., et al.. PPAR-γ agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-κB pathways. Blood, 2005, 106: 3888-3894